RecruitingPHASE1, PHASE2NCT03317158
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Studying Muscular tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Noah Hahn, M.D.
- Principal Investigator
- Noah M. Hahn, MDHoosier Cancer Research Network
- Intervention
- Durvalumab (Cohort 1-3)(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2027
Study locations (12)
- BCG Oncology, Phoenix, Arizona, United States
- Stanford University, Stanford, California, United States
- Rush University Medical Cneter, Chicago, Illinois, United States
- Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- University of Nebraska Medical Center, Omaha, Nebraska, United States
- Columbia University Irving Medical Center, New York, New York, United States
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
- Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Collaborators
AstraZeneca · Hoosier Cancer Research Network
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03317158 on ClinicalTrials.govOther trials for Muscular tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07144319Exploration of Novel AI-enabled Blue Light Enhanced CystoscopyPhotocure
- RECRUITINGPHASE2NCT07475403Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerTianjin Medical University Second Hospital
- RECRUITINGPHASE2NCT07475806A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their BladderAstellas Pharma Global Development, Inc.
- RECRUITINGNANCT07431788The Effect of Uterine Manipulator Use During Abdominal Hysterectomy on Postoperative Sexual FunctionErkan Gol
- RECRUITINGNANCT07339761Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention StudyUniversity of Aarhus
- RECRUITINGPHASE2NCT07363057A Study to Evaluate the Effects of the Combination of GI-102 With GIB-7 on Biomarkers of Aging in Healthy Adults and Cancer SurvivorsGI Innovation, Inc.
- RECRUITINGPHASE3NCT06919965A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGNANCT07001670Investigation of the Effects of Tele-Yoga Training in Individuals With Lung Cancer Undergoing Lung Resection SurgeryIstanbul University